Winter 2016/2017
Regulation

The FDA’s Dr. No’s

The agency’s fear of Type II errors inhibits drug development and harms patients

Winter 2016/2017
Regulation

Beyond the Low‐​Hanging Fruit

How should policymakers judge environmental regulations when marginal costs are rising and marginal benefits are falling?